Drug intelligence / Profile preview

LM303

Development stage: Phase 1
Lead developer: Suzhou Lanma Medical Technology
Administration: Injection

Overview

LM303 is an investigational drug being developed by Suzhou BlueHorse Therapeutics for the treatment of advanced solid tumors. It is administered via injection and is in early-phase clinical trials (Phase 1) to evaluate its safety and efficacy in patients with various advanced cancers, including melanoma, non-small cell lung cancer, and cervical cancer. The precise mechanism of action for LM303 remains unknown at this time. The drug has not received any regulatory approvals or special designations and is not yet marketed in any country.

Beyond the preview

Go deeper on LM303.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM303.

Explore the full profile